Treatment of visual hallucinations in schizophrenia by acetylcholinesterase inhibitors: A case report

Iranian Journal of Psychiatry

Volumn 6, Issue 4, 2011, Pages 161-163

  Abad, Nazir Hashemi ^a   Doulatabad, Najafi Shala ^a   Mohammadi, Ali ^a   Srazi, Hamid Reza Ghafarian ^a,b  

^a YASUJ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acetyl cholinesterase inhibitors; Hallucinations; Schizophrenia; Visual perception

Indexed keywords

EID: 84856761491     PISSN: 17354587     EISSN: 20082215     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Tandon R, Keshavan M, Nasrallah H. Schizophrenia epidemiology and etiology. Schizophrenia research. 2008; 102: 1-18. doi:10.1016/j.schres.2008.04.011
2. Kersten D, Mamassian P, Yuille A. Object perception as bayesian inference. Annu Rev Psychology. 2004; 55:271-304. doi: 10.1146/annurev.psych.55.090902.142005.(Cross Ref)
3. Friston K. A theory of cortical responses. Phil Trans R Soc B. 2005; 360: 815-836. doi: 10.1098/rstb.2005.1622.(PMC free article)(PubMed)(Cross Ref)
4. Yu D, Dayan P. Acetylcholine in cortical inference. Neural network. 2002; 15: 719-730. doi: 10.1016/S0893-6080(02)00058-8.(PubMed)(Cross Ref)
5. Jeffery L. Cholinesterase inhibitors: A new class of psychotropic compounds. Am J Psychiatry. 2000;157:4-15
6. Sachin SP, Azizah A, Pamela J, Sukhi S. Acetylcholinesterase inhibitors (AchEI,s) for the treatment of visual hallucination in schizophrenia: a case report. BMC psychiatry. 2010;10: 68. doi:10.1168/147-244x-10-68
7. Edwards K, Royall D, Hershey L, Lichter D, Hake A, Farlow M, Pasquier F, Johnson S. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24 week open-label study. Dementia and Geriatric Cognitive Disorders. 2007; 23(6): 401-5. doi: 10.1159/000101512.(PubMed)(Cross Ref)
8. Fabbrini G, Barbanti P, Aurilia C, Pauletti C, Lenzi GL, Meco G. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurological Sciences. 2002; 23(1): 41-43. doi: 10.1007/s100720200022.(Cross Ref)
9. Cummings JL. Cholinesterase Inhibitors: A new Class of Psychotropic Compounds. Am J Psychiatry. 2000; 157:(1) 4-15.
10. Cummings JL, Askin-Edgar S. Evidence for Psychotropic Effects of Acetylcholinesterase Inhibitors. CNS Drugs. 2000; 13:(6) 385-395. doi: 10.2165/00023210-200013060-00001.(Cross Ref).
11. Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Current Medical Research and Opinion. 2002; 18(5):258-64. doi: 10.1185/030079902125000813.(PubMed)(Cross Ref).
12. David B, Murat E, Ian M, Peter P, Dag A, Chuanchieh H, Roger L. Effect of Rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Movement Disorder.2006;21:1899-1907.doi:10.1002/mds.21077.
13. Edwards KR, Hershey L, Wray L, Bednarczyk EM, Lichter D, Farlow M, Johnson S.. Efficacy and Safety of Galantamine in Patients with Dementia with Lewy Bodies: A 12-Week Interim Analysis. Dementia and geriatric cognitive disorder. 2004;17:40-48 (DOI: 10.1159/000074681)
14. Lenzi A, Maltinti E, Poggi E, Fabrizio L, Coli E. Effect of Rivastigmine on cognitive function and quality of life in patients with schizophrenia. Clinical neuropharmacology 2003; 26: 317-32.
15. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale for schizophrenia. Schizophr Bull. 1987; 13: 261-276.